BPC-157 for UC and MS: the evidence
Rodent models show gut-repair effects, but no human trial has published results for UC or MS. Interaction data with azathioprine or teriflunomide is absent.
Why we wrote this. People on immunosuppressants asking about BPC-157 and TB-500 face a drug-interaction gap the community discussion rarely acknowledges. The honest answer matters more here than elsewhere.
In this article (6 sections)
This article is for educational purposes only. It does not constitute medical advice, and it does not apply to any individual's clinical situation. People with autoimmune diseases who are on prescription immunosuppressants should discuss any new compound with the clinician managing their care before taking it.
A recurring question in peptide communities is whether BPC-157 or TB-500 might help with inflammatory conditions like ulcerative colitis (UC) or multiple sclerosis (MS). The question makes sense at first glance: both peptides have a reputation for anti-inflammatory and tissue-repair effects in rodent studies, and people with UC or MS deal with exactly the kinds of inflammation and tissue damage those animal studies describe. The honest answer is more complicated than the online discussion usually admits.
What the BPC-157 research actually covers
BPC-157 is a 15-amino-acid synthetic peptide derived from a sequence in human gastric juice. The preclinical literature is large and frequently positive: rodent models of ulcerative colitis and gastric ulcer show reduced lesion size with BPC-157 administration, and the proposed mechanisms, including angiogenesis promotion, nitric-oxide pathway modulation, and gut-brain axis signalling, are internally consistent[1]. A 2012 review in Current Medicinal Chemistry described BPC-157 as having an antiulcer effect with potential applicability to IBD on the basis of that animal evidence, and noted a Phase 2 trial was under way[2].
Multiple papers from the same research group, between 2018 and 2024, mention that BPC-157 "has been tested in ulcerative colitis and multiple sclerosis trials"[3][4]. The US Anti-Doping Agency has confirmed that BPC-157 "has been investigated for inflammatory bowel disease" but states that "studies appear to have been cancelled or stopped without any published conclusions"[5]. That is the key detail: the references to clinical trials appear in review papers authored by the same group that conducted the preclinical work, and the trial results have not been published in the peer-reviewed literature as of August 2026. There is no completed, published randomised controlled trial of BPC-157 for UC or MS with reported efficacy or safety outcomes.
What the TB-500 research covers
TB-500 is a heptapeptide fragment of thymosin beta-4, a protein involved in actin sequestration and tissue-repair signalling. Its preclinical literature covers wound healing, cardiac protection, and corneal injury recovery. The closest thing to a human clinical trial in the thymosin beta-4 literature is a small Phase 3 ophthalmology trial of a topical formulation (RGN-259) for neurotrophic keratopathy[6]. There is no published human data on TB-500 specifically in UC, MS, or any autoimmune disease. The 2026 review by Mendias and Awan in Sports Medicine concluded that unapproved peptides like TB-500 demonstrate favourable tissue-repair outcomes in animal models but that "rigorous human safety data are scarce, and there is potential for serious harm to patients"[7].
The immunosuppressant interaction problem
The question takes on a different character when the person asking is on prescription immunosuppressants, as many people with MS and UC are. Teriflunomide (sold as Aubagio), used in relapsing MS, inhibits a mitochondrial enzyme involved in T-cell proliferation. Azathioprine, a common UC maintenance drug, suppresses lymphocyte production by interfering with purine synthesis. Both work through defined mechanisms on specific immune pathways.
BPC-157 and TB-500 are described in animal research as having anti-inflammatory and tissue-repair properties. Whether those properties interact with immunosuppressant drugs, potentially counteracting them, compounding their effects, or triggering unexpected responses in an already-modulated immune system, is simply not known. There are no published pharmacokinetic or pharmacodynamic interaction studies for either peptide with teriflunomide or azathioprine[7]. The absence of data here is not reassurance: it means the risk cannot be characterised.
The grey-market supply risk
Both BPC-157 and TB-500 are sold online as research chemicals, not as pharmaceutical-grade medicines subject to quality controls[8]. Independent testing of grey-market peptide vials has found purity failures, identity mismatches, and microbial or endotoxin contamination above pharmaceutical thresholds. For a person with UC or MS already taking immunosuppressants, a contaminated injectable compound carries a meaningfully different risk profile than it does for a healthy adult: an immunosuppressed system may handle infection from a contaminated vial less effectively. See our overview of grey-market BPC-157 risks for more on the supply-chain picture.
What remains unknown
The core knowledge gaps for someone with MS or UC considering these peptides are not marginal. Researchers do not know whether BPC-157's gut-repair effects in rodent colitis models translate to human UC, because no completed trial with published results exists for this indication. Researchers do not know whether either peptide is safe in combination with teriflunomide or azathioprine, because that combination has not been studied. Researchers do not know whether the angiogenic and repair properties of these compounds interact with the specific immune pathways that immunosuppressant drugs are already modulating. These are not gaps that community experience fills.
The regulatory picture
Neither BPC-157 nor TB-500 has a marketing authorisation from the FDA, EMA, MHRA, or any national medicines agency in the countries this site covers[8][9]. Both are on the WADA Prohibited List. BPC-157 is in Category 2 on the FDA's 503A bulk drug substances list for pharmacy compounding, indicating insufficient evidence of safety and effectiveness to support compounding use. The FDA Pharmacy Compounding Advisory Committee reviewed BPC-157 in July 2026. Whatever the outcome of that review, it does not change BPC-157's status as an unapproved new drug.
The decision about whether to consider either peptide belongs with the clinicians managing the MS and the UC. They are the people who know the disease activity, the treatment regimen, and the individual risk picture. For more on BPC-157's evidence base, see the BPC-157 overview, and for the regulatory picture by country, see the regulation pages.
Frequently asked
Has BPC-157 been tested in humans for ulcerative colitis?
Multiple review papers from the Sikiric research group refer to a Phase 2 clinical trial of BPC-157 in ulcerative colitis. However, results from that trial have not been published in the peer-reviewed literature as of August 2026. The US Anti-Doping Agency has noted that studies appear to have been cancelled or stopped without published conclusions. There is no completed, published randomised controlled trial of BPC-157 for UC with reported outcomes.
Could BPC-157 or TB-500 interfere with teriflunomide or azathioprine?
This is not known. There are no published human pharmacokinetic or pharmacodynamic interaction studies for either peptide with either drug. BPC-157 is described in animal research as modulating immune and inflammatory pathways, and both teriflunomide and azathioprine work through defined immunosuppressive mechanisms. Whether those effects interact in people, and how, has not been studied. The absence of data is not reassurance.
Are BPC-157 and TB-500 legal to buy for personal use?
Neither peptide has a marketing authorisation from the FDA, EMA, MHRA, or any national medicines agency we cover. Both are sold online as research chemicals, not pharmaceutical-grade medicines. Personal possession is generally not a scheduled-drug offence in most of our coverage area, but that does not make the products legal medicines or safe. Country-specific detail is on the regulation pages.
What should someone with MS or UC do if they are curious about these peptides?
Bring the question to the clinician managing the condition, whether that is a neurologist, gastroenterologist, or both. The combination of an active autoimmune disease, prescription immunosuppressants, and an unregulated injectable compound with unknown drug-interaction data is a clinical risk question that belongs in a consultation. This site provides educational information; it does not provide medical advice.
Sources
- [1]Seiwerth et al. (2021): Stable Gastric Pentadecapeptide BPC 157 and Wound Healing (Front Pharmacol; PMID 34267654)Tier 1 · primary↩
- [2]Sikiric et al. (2012): Focus on ulcerative colitis, stable gastric pentadecapeptide BPC 157 (Curr Med Chem; PMID 22300085)Tier 1 · primary↩
- [3]Sikiric et al. (2018): Novel Cytoprotective Mediator, Stable Gastric Pentadecapeptide BPC 157. Vascular Recruitment and Gastrointestinal Tract Healing (Curr Pharm Des; PMID 29879879)Tier 1 · primary↩
- [4]Sikiric et al. (2024): New studies with stable gastric pentadecapeptide protecting gastrointestinal tract (Inflammopharmacology; PMID 38980576)Tier 1 · primary↩
- [5]USADA: BPC-157 is prohibited in sportTier 2 · expert↩
- [6]Sosne et al. (2023): 0.1% RGN-259 (thymosin beta-4) ophthalmic solution promotes healing in neurotrophic keratopathy: randomized Phase III trial (Int J Mol Sci; PMID 36613994)Tier 1 · primary↩
- [7]Mendias and Awan (2026): Safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance (Sports Med; PMID 41966639)Tier 1 · primary↩
- [8]U.S. DoD Operation Supplement Safety: BPC-157, a prohibited peptide and an unapproved drugTier 1 · primary↩
- [9]WADA Prohibited List 2026Tier 1 · primary↩
No revisions yet. First published .